Nurix Therapeutics (NASDAQ:NRIX) had its price target hoisted by analysts at Needham & Company LLC from $35.00 to $44.00 in a research note issued on Friday, Anlyst Ratings reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price target points to a potential upside of 9.34% from the stock’s previous close.
Several other equities analysts also recently commented on NRIX. Robert W. Baird began coverage on Nurix Therapeutics in a report on Wednesday, November 18th. They set an “outperform” rating and a $40.00 price target on the stock. Zacks Investment Research upgraded shares of Nurix Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, December 15th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $38.60.
Shares of NRIX stock opened at $40.24 on Friday. Nurix Therapeutics has a 12 month low of $15.21 and a 12 month high of $52.38. The company’s 50 day moving average is $39.28.
Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Monday, October 19th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.18). The business had revenue of $4.09 million during the quarter, compared to the consensus estimate of $7.35 million. Equities research analysts forecast that Nurix Therapeutics will post -1.97 EPS for the current year.
Institutional investors have recently made changes to their positions in the company. Victory Capital Management Inc. acquired a new stake in shares of Nurix Therapeutics in the third quarter worth $394,000. TD Asset Management Inc. bought a new position in Nurix Therapeutics in the third quarter worth $1,325,000. Strs Ohio bought a new position in Nurix Therapeutics in the third quarter worth $97,000. New York State Common Retirement Fund bought a new position in Nurix Therapeutics in the third quarter worth $221,000. Finally, California Public Employees Retirement System bought a new position in Nurix Therapeutics in the third quarter worth $879,000. Institutional investors and hedge funds own 34.36% of the company’s stock.
About Nurix Therapeutics
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications.
See Also: What does earnings per share mean?